Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of SPX-303 in advanced solid tumors
CTR20261052Phase 2Active
- Sponsor
- CureBay Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SPX-303 in colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC) and 5 more (4 arms), sponsored by CureBay Biopharmaceuticals. Primary endpoints: Safety and tolerability, RP2D/MTD determination and 2 more. Started Mar 2026; status: active.
02
Drugs
SPX-303
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)gastric cancer (GC)melanoma
Beyond the preview
Go deeper on CTR20261052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261052.